ERBB2 and breast carcinoma: Herceptin has boosted the interest of clinicians in immunotherapy based on this molecule as it represents the first mAb approved for therapeutic use with proved survival benefit in patients with HER-2-positive breast cancer with metastasis (Baselga et al, 1996; Slamon et al, 2001).